BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Month: April 2022

3 posts
BenchSci Expands Advisory Board with New Pharma R&D Leaders

Biotech NewsBenchSci Expands Advisory Board with New Pharma R&D Leaders

  • BioTech Health X
  • April 21, 2022
BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda…
0 Shares
0
0
0
0
0
0
0
EF Hutton Initiates Coverage of Cel-Sci CVM with 17 Price Target Ahead of Rumored News

Biotech NewsEF Hutton Initiates Coverage of Cel-Sci (CVM) with $17 Price Target Ahead of Rumored News

  • BioTech Health X
  • April 7, 2022
Tim Moore, CFA an Analyst at EF Hutton has recently published a report citing the opportunities for growth…
0 Shares
0
0
0
0
0
0
0
Legend Biotech Appoints Dr Guowei Fang Head of Global Research and Early Development

Biotech NewsLegend Biotech Appoints Dr. Guowei Fang As Head of Global Research and Early Development

  • BioTech Health X
  • April 1, 2022
Global biotechnology company Legend Biotech Corporation (NASDAQ: LEGN) announced today that Guowei Fang, Ph.D. will take over as…
1 Shares
0
1
0
0
0
0
0
Recent Posts
  • From $10 to $23? Why Niagen Bioscience (NAGE) Could Be the Next Big Biotech Success Story
  • Wall Street Is Going Crazy Over UroGen Pharma (URGN) – Here’s Why it Could Be a 2025 Winner
  • Cel-Sci (CVM) Could Skyrocket 3,000% – Here’s Why Investors Are Buzzing
  • FDA Decision Incoming! Apellis Pharmaceuticals (APLS) Could Be the Next 10X Biotech Stock!
  • From NeuroBo to MetaVia (MTVA): This Biotech Just Went All-In on Obesity and Liver Disease
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • July 28, 2025
    From $10 to $23? Why Niagen Bioscience (NAGE) Could Be the Next Big Biotech Success Story
    • July 28, 2025
    Wall Street Is Going Crazy Over UroGen Pharma (URGN) – Here’s Why it Could Be a 2025 Winner
    • July 28, 2025
    Cel-Sci (CVM) Could Skyrocket 3,000% – Here’s Why Investors Are Buzzing
    • July 28, 2025
    FDA Decision Incoming! Apellis Pharmaceuticals (APLS) Could Be the Next 10X Biotech Stock!
    • July 23, 2025
    From NeuroBo to MetaVia (MTVA): This Biotech Just Went All-In on Obesity and Liver Disease
Recent Posts
  • Alterity Therapeutics (ATHE) is One FDA Meeting Away From a Major Breakout
    • July 23, 2025
  • Liminatus Pharma (LIMN) Might Be the Most Disruptive Micro-Cap on NASDAQ
    • July 23, 2025
  • Thermo Fisher (TMO) Is Everywhere—And That’s Exactly Why It’s Winning
    • July 23, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (267)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top